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Although the mechanism is unknown, clinical trials have sug-
gested that intravenous beta-adrenergic blockade may prevent 
early cardiac rupture after myocardial infarction. Previous stud-
ies have examined effects of beta-blockers on global left ventricu-
lar function after myocardial infarction; however, few data exist 
regarding their immediate effects on regional function or in 
patients after successful reperfusion. Therefore, 65 patients in 
whom thrombolysis with or without coronary angioplasty 
achieved reperfusion at 4.6 ± 1.7 h from symptom onset were 
studied. Low osmolarity contrast ventriculograms were obtained 
immediately before and after administration of 15 mg of intrave-
nous metoprolol (n = 54) or placebo (n = 11). 
Intravenous metoprolol immediately decreased heart rate 
(from 92 to 76 beats/min, p < 0.0001), increased left ventricular 
diastolic volume (from 150 to 163 ml, p < 0.0001) and systolic 
volume (from 72 to 77 ml, p < 0.0005) but did not change systolic 
and diastolic pressures. Although there was no difference in 
ejection fraction after metoprolol, centerline chord analysis re-
Before the era of reperfusion therapy for acute myocardial 
infarction, several trials (1-4) demonstrated that the use of 
beta-adrenergic blocking agents resulted in improved long-
term survival for patients with this condition. However, the 
need for immediate versus delayed administration of beta-
blockers has remained controversial. The First International 
Study of Infarct Survival (ISIS-I) (5) as well as the GISSI 
recently reported that the mortality reduction after early 
intravenous beta-blockade may be due to prevention of early 
cardiac rupture (5,6). The mechanism for reduction in rup-
ture is not known and the ISIS investigators (5) could not 
demonstrate a relation between reduction in infarct size and 
prevention of cardiac rupture after beta-adrenergic block-
ade. Although some data exist regarding the effects of 
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vealed reduced noninfarct zone motion (from 0.41 to 0.12 SD/ 
chord, p < 0.05), improved infarct zone motion (from -3.1 to 
-2.9 SD/chord, p < 0.01) and smaller circumferential extent of 
hypokinesia (from 30 to 27 chords, p < 0.05). Patients with 
dyskinesia of the infarct zone had the most striking improvement 
in infarct zone wall motion. Because these changes occurred 
immediately after beta-blockade, they could not be attributed to 
myocardial salvage. No significant changes in heart rate, left 
ventricular volumes or regional wall motion were apparent in the 
control group. 
Thus, intravenous beta-blockade reduced wall motion of the 
noninfarct zone and enhanced infarct zone wall motion after 
reperfusion in humans, independent of myocardial salvage. 
Whether these changes are due to alteration in heart rate, 
reduction in ischemia or reduction in forces from the opposing 
hypercontractile wall will require further investigation. 
(J Am Coil CardioI1991;17:1382-7) 
beta-blockers on global left ventricular function in humans 
(7,8), few data exist regarding their effects on regional left 
ventricular function. Furthermore, these agents have not 
been extensively evaluated in patients who have undergone 
reperfusion therapy. Therefore, this study was undertaken 
to determine the acute effects of intravenous beta-blockade 
on regional and global left ventricular function after reper-
fusion therapy for acute myocardial infarction. 
Methods 
Study design. Patients with acute myocardial infarction 
who presented to the University of Kentucky Medical Center 
between October 1988 and January 1989 were considered for 
enrollment in the study. Inclusion criteria included electrocardio-
graphic evidence of ST segment elevation 2:: 1 mm in two contig-
uous leads, chest pain duration <6 h before initiation of reperfu-
sion therapy and uneventful completion of emergency 
catheterization and left ventriculography. 
Excluded from the study were patients being treated with 
a beta-adrenergic blocking drug and those with contraindi-
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cations for such agents including a systolic blood pressure 
<90 mm Hg, clinical evidence of bronchospasm or conges-
tive heart failure, left ventricular end-diastolic pressure 
> 35 mm Hg, or an ejection fraction <30% by visual estima-
tion. Patients were also excluded for the presence of arrhyth-
mias such as atrial fibrillation or frequent ventricular prema-
ture beats, which may interfere with ventricular wall motion 
analysis, a technically inadequate baseline ventriculogram or 
ongoing ischemic chest pain. The investigational protocol 
was approved by the Institutional Review Board and all 
patients gave informed consent before participation. 
The study design was as follows: Sixty-five patients with 
acute myocardial infarction underwent reperfusion therapy 
that consisted of intravenous administration of one or more 
thrombolytic agents (n = 50), thrombolytic therapy with 
salvage coronary angioplasty for failed recanalization (n = 9) 
or primary angioplasty (n = 6) performed within 6 h of chest 
pain onset. The choice of therapy was determined by the 
attending physician and patient. The study protocol was 
initiated after completion of emergency catheterization and, 
when necessary, coronary angioplasty. Baseline heart rate 
and left ventricular pressures were measured with use of 
fluid-filled catheters, Baseline left ventriculography was per-
formed at 60 frames/s with use of a low osmolarity contrast 
agent delivered at 12 to 15 cels over 3 to 4 s. The first 54 
patients were then given 15 mg of intravenous metoprolol, 
administered in three divided doses over 8 min. Two minutes 
after the last dose of metoprolol, measurements of heart rate 
and left ventricular pressures and left ventriculography were 
repeated. No additional medications were given between 
angiograms. To determine the effect of contrast medium 
alone, 11 additional patients were designated as a control 
group and underwent contrast ventriculography before and 
10 min after administration of 15 ml dextrose in distilled 
water as a placebo. A radiopaque grid of known dimensions 
was filmed at the completion of the final ventriculogram. 
Angiographic analysis. The 30° right anterior oblique end-
diastolic and end-systolic endocardial outlines from a non-
postpremature sinus beat and the outline of the grid were 
traced by a single technician who did not know the time of 
the study or the study medication. With use of a tablet 
digitizer, the outlines were transferred into a Compaq Desk 
Pro 286 computer containing a Digisonics catheterization 
laboratory analysis system. Left ventricular volumes and 
ejection fraction were calculated by the area-length method 
(9). Regional wall motion of the infarct and noninfarct zones 
was determined by the centerline chord method (10). Briefly, 
endocardial motion was measured along 100 chords drawn 
perpendicular to a centerline constructed midway between 
the end-diastolic and end-systolic contours. The measured 
motion of the 100 chords was normalized for heart size by 
dividing by the end-diastolic perimeter. Within each terri-
tory, regional wall motion was calculated as the mean 
motion of one half of the most abnormally contracting 
contiguous chords and expressed in standard deviations per 
chord. Hypokinesia is indicated by negative values and 
hyperkinesia by positive values. The length of the hypoki-
netic segment was defined as the number of contiguous 
chords with wall motion scores < - 2 SD/chord from normal. 
Technically inadequate ventriculograms due to ventricular 
arrhythmias or inadequate opacification were excluded from 
analysis. 
Infarct vessel patency was determined according to the 
Thrombolysis in Myocardial Infarction (TIM!) study classi-
fication (11). The percent diameter stenosis of infarct and 
noninfarct vessels was determined by caliper measurement 
of coronary angiograms. Multivessel coronary disease was 
defined as >50% stenosis in one or more vessels remote 
from the infarct artery. 
Statistical analysis. Analysis of variance for repeated 
measures was used to determine the significance of changes 
in hemodynamic measurements within each group. Changes 
in left ventricular volume and function within each group 
were determined by Student's t test for paired data and 
differences between groups by Student's t test for unpaired 
data. Values are expressed as mean values ± SD unless 
otherwise indicated. A p value sO.05 was considered signif-
icant. 
Results 
Clinical and angiographic characteristics (Table 1). There 
were no significant differences in baseline clinical or angio-
graphic characteristics between beta-blocker (n = 54) and 
control (n = 11) groups. Fifty-four patients received intra-
venous metoprolol. One patient with a large anterior myo-
cardial infarction did not complete the protocol because 
congestive heart failure developed after administration of 
only 5 mg of metoprolol. The remaining 53 patients had no 
adverse effects and complete hemodynamic data were ob-
tained. The mean age of the beta-blocker group was 54 ± 10 
years and 74% were male. An anterior myocardial infarction 
was present in 39% of patients and an inferior or lateral 
Table 1. Baseline Clinical and Angiographic Characteristics of 
65 Patients 
Beta-Blocker Control 
(n = 54) (n = 11) 
Age (yr) 54 ± 10 53 ± 11 
Gender (% male) 74 73 
Infarct vessel (%) 
LAD 39 36 
Circumflex 13 18 
Right 48 45 
Thrombolytic therapy (%) 93 82 
Acute PICA (%) 22 27 
Infarct vessel patency (%) 96 100 
Reperfusion time (h) 4.6 ± 1.7 4.7 ± 1.2 
Multivessel disease (%) 54 64 
'No significant (p < 0.05) differences between the two groups. LAD = left 
anterior descending coronary artery: PTCA = percutaneous transluminal 
coronary angioplasty. 
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infarction in 61%. The infarct-related artery was the left 
anterior descending coronary artery in 39%, the left circum-
flex coronary artery in 13% and the right coronary artery in 
48% of patients. 
Thrombolytic therapy was administered to 93% of pa-
tients and consisted of intravenous recombinant tissue-type 
plasminogen activator (rt-PA) in 46%, streptokinase in 4% 
and the combination of streptokinase with half-dose tissue 
plasminogen activator in 43% (12). Coronary angioplasty 
was performed in 22% of the patients in the beta-blocker 
group either as a direct reperfusion strategy in three patients 
or as a salvage procedure after failed thrombolysis in nine. 
Infarct vessel patency was achieved in 96% of patients. Two 
patients who received metoprolol had a limited inferior 
infarction with total occlusion of a very distal vessel; hence, 
it was elected not to perform angioplasty in these patients. 
Angiographic documentation of infarct vessel patency oc-
curred a mean of 4.6 ± 1.7 h after the onset of chest pain. 
Single-vessel coronary disease was found in 46% of patients, 
two-vessel disease in 34% and three-vessel disease in 20%. 
Hemodynamics (Table 2). Baseline heart rate (92 ± 12 vs. 
90 ± 11 beats/min), left ventricular systolic pressure (127 ± 
19 vs. 124 ± 29 mm Hg) and end-diastolic pressure (21 ± 8 
vs. 19 ± 7 mm Hg) were similar in the beta-blocker and 
control groups. After injection of contrast medium for the 
first ventriculogram, there was a transient, slight increase in 
heart rate, a decrease in left ventricular systolic pressure and 
an increase in end-diastolic pressure in both groups. Before 
the second ventriculogram, left ventricular systolic and 
end-diastolic pressures remained unchanged but heart rate 
decreased from 92 ± 12 to 76 ± 10 beats/min (p < 0.0001) in 
the metoprolol group. No significant changes in heart rate or 
left ventricular pressure occurred between the first and 
second ventriculograms in the control group. 
Left ventricular function. Compared with values on base-
line ventriculography, intravenous beta-blockade resulted in 
a significant increase in left ventricular end-diastolic volume 
(from 150 ± 41 ml to 163 ± 41 ml, p < 0.0001) and 
end-systolic volume (from 72 ± 26 ml to 77 ± 26 ml, p < 
0.0005) (Fig. I). Conversely, in the placebo group left 
Table 2. Hemodynamic Measurements in 65 Patients 
Heart rate (beats/min) 
Baseline 
Treatment 
LV systolic pressure (mm Hg) 
Baseline 
Treatment 
LV EDP (mm Hg) 
Baseline 
Treatment 
Beta-Blocker 
Group 
(metoprolol) 
(n = 54) 
92 ± 12 
76 ± 10 
127 ± 19 
124 ± 19 
21 ± 8 
22 ± 7 
Control 
Group 
(n = 11) 
90 ± II 
90 ± II 
124 ± 29 
125 ± 28 
19 ± 7 
20 ± 8 
EDP = end-diastolic pressure; LV = left ventricular. 
p Value 
NS 
0.005 
NS 
NS 
NS 
NS 
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Figure 1. Ejection fraction and global left ventricular volume before 
and after beta-blockade. 
ventricular systolic and diastolic volumes were similar dur-
ing the first and second ventriculograms. Baseline ejection 
fraction was 53 ± 10% (range 36% to 76%) and was un-
changed after beta-blockade. As expected, ejection fraction 
before and after administration of placebo was also un-
changed (50 ± 16%). 
Hypokinesia of the infarct zone (-3.1 ± 1.0 SDlchord) 
and hyperkinesia of the noninfarct zone (+0.41 ± 1.2 SD/ 
chord) were present on baseline ventriculography in the 
metoprolol group (Fig. 2). After intravenous beta-blockade, 
regression of hyperkinesia in the noninfarct zone occurred 
with a decrease in wall motion from +0.41 SD/chord to 
+0.12 ± 1.1 SD/chord (p < 0.05). Small, but highly signifi-
cant improvement in infarct zone function (from - 3.1 ± 1.0 
to -2.9 ± 0.9 SD/chord; p < 0.01) was also apparent after 
beta-blockade. Furthermore, the length of the hypokinetic 
segment was reduced from 30 chords at baseline to 27 chords 
after beta-blockade (p < 0.05). Regional wall motion of the 
infarct and noninfarct zones and the length of the hypoki-
netic segment did not change between the first and second 
ventriculograms in the placebo group. 
Regression analysis demonstrated that the improvement 
in infarct zone function after beta-blockade was related to 
Figure 2. Intravenous administration of the beta-adrenergic block-
ing agent metoprolol immediately improved infarct zone wall motion 
(SD/chord) and blunted "compensatory hyperkinesia" of the non-
infarct zone. 
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Figure 3. Individual data points for infarct zone function at baseline 
(Pre) and immediately after (Post) intravenous administration of the 
beta-adrenergic blocking agent metoprolol in 39 patients. Infarct 
zones demonstrating akinesia and dyskinesia (wall motion score 
ranging from -3.0 SD/chord to -5.0 SD/chord) demonstrated 
improvement after beta-blockade. 
regression of hyperkinesia of the noninfarct zone (regression 
coefficient 0.26, p = O.OS), as well as the degree of baseline 
impairment of the infarct zone (regression coefficient 0.S3, 
p = 0.0002). Infarct zones demonstrating akinesia and dys-
kinesia (wall motion scores ranging from -3.0 SD/chord to 
-S.O SD/chord) demonstrated greater improvement after 
beta-blockade (0.33 SD/chord, p < O.OOOS) compared with 
minimal change ( -0.08 SD/chord) in a ventricle that was less 
severely injured (Fig. 3). 
Discussion 
Our data demonstrate that after reperfusion therapy for 
myocardial infarction, immediate beta-adrenergic blockade 
increases left ventricular diastolic and systolic volumes, 
reduces wall motion of the noninfarct zone and improves 
wall motion of the infarct zone. Because these changes 
occurred immediately after beta-blockade, they could not be 
attributed to myocardial salvage. The improvement in infarct 
zone wall motion, which was particularly apparent in pa-
tients with a large area of dyskinesia, may be one mechanism 
by which beta-blockade reduces cardiac rupture after myo-
cardial infarction. Potential explanations for this improve-
ment in infarct zone wall motion include alteration in heart 
rate or loading conditions, reduction in ischemia or reduc-
tion in forces from the opposing hypercontractile wall. 
Effect of heart rate and left ventricular volume. In the 
setting of acute myocardial infarction, beta-adrenergic 
blockade has been demonstrated to reduce myocardial work 
load and oxygen demand through a reduction in heart rate, 
blood pressure and myocardial wall motion. Because coro-
nary flow occurs primarily during diastole, reduction in heart 
rate may also result in an increase in myocardial perfusion. 
In animal models of ischemia, beta-blockade resulted in a 
favorable redistribution of blood flow to ischemic suben-
docardial regions (13-1S), reduced infarct size and improved 
regional myocardial function (16,17). In our study changes in 
regional wall motion occurred immediately after beta-
blockade; therefore, they could not be attributed to myocar-
dial salvage. Acute reduction in infarct zone ischemia is also 
unlikely because the infarct vessel was already patent in 96% 
of patients and all patients experienced complete resolution 
of chest pain and were hemodynamically stable. Immediate 
improvement in infarct zone function due to reperfusion 
alone is also unlikely because these changes were not 
apparent in the control group and improvement in regional 
myocardial function due to reperfusion usually occurs over 
several days (18). 
The effects of changes in heart rate on ventricular volume 
and function have been extensively evaluated. Increasing 
heart rate by atrial pacing is associated with a decrease in left 
ventricular systolic and diastolic volumes (19,20). Although 
rapid atrial pacing (140 to 160 beats/min) has occasionally 
been associated with a significant reduction in ejection 
fraction (21,22), alteration of heart rate within a normal 
range (64 to 98 beats/min) produced minimal or no change in 
ejection fraction (20,23). Therefore, the decrease in mean 
heart rate from 92 to 76 beats/min after beta-blockade in our 
study may account for the increase in left ventricular vol-
umes without affecting global ejection fraction. Although the 
increase in end-diastolic volume may alter the motion mea-
sured along each chord in the centerline analysis, the cen-
terline chord program controlled for heart size by dividing by 
the end-diastolic perimeter (10). Furthermore, the increase 
in end-diastolic volume would be expected to improve wall 
motion in both infarct and noninfarct zones. Thus, it is 
unlikely that the increase in left ventricular volume after 
beta-blockade is responsible for the observed changes in 
regional wall motion. 
Effect of loading conditions. Vasodilators such as nitrate 
preparations, hydralazine and captopril have been demon-
strated to improve infarct zone function (24-26) and prevent 
infarct expansion (27-29), presumably by altering loading 
conditions. Furthermore, in an open chest canine study (30), 
the extent of left ventricular ischemic dysfunction was 
improved by lowering left ventricular pressure and worsened 
by increasing left ventricular pressure using vena caval and 
aortic constriction, respectively. Although beta-blockers are 
known to lower blood pressure (7,8), no acute changes in left 
ventricular pressure occurred in our patient groups. Further-
more, the slight increase in left ventricular end-diastolic 
pressure after radiographic contrast medium produced no 
1386 GRINES ET AL. 
EFFECTS OF BETA-BLOCKADE ON REGIONAL VENTRICULAR FUNCTION 
lACC Vol. 17. No.6 
May 1991: 1382-7 
change in left ventricular volumes or regional or global left 
ventricular function in the control group. Therefore, changes 
in infarct and noninfarct zone wall motion in our series 
cannot be attributed to reduction in blood pressure with 
beta-blockade or volume loading with radiographic contrast 
medium. 
Mechanical interaction between infarct and noninfarct 
zones. Animal studies (31-37) have clearly demonstrated 
that wall motion of the ischemic area progressively worsens 
and that paradoxic systolic expansion occurs within minutes 
of acute occlusion of an epicardial coronary artery. An 
increase in wall thickening and endocardial wall motion has 
been described in remote nonischemic areas in both exper-
imental animals (32-40) and humans (41-44). Hyperfunction 
of the noninfarct zone has usually been attributed to utiliza-
tion of the Frank-Starling mechanism (32-36), although some 
investigators have suggested increased sympathoadrenergic 
stimulation (37,45), neurovascular reflex (38) or regional left 
ventricular unloading (39-41) as the mechanism. 
Hyperkinesia of the nonischemic area has been consid-
ered to provide important compensation for decreasedfunc-
tion in the ischemic zone. However, Lew et al. (40) demon-
strated in a canine model that increased shortening in the 
nonischemic region may provoke expansion of ischemic 
myocardium during isovolumetric systole without a signifi-
cant compensatory increase in ejection phase shortening. 
Yamanishi et a1. (41) examined contractile function in isch-
emic and nonischemic myocardial regions using contrast 
ventriculography in 12 patients with single vessel coronary 
disease before and after rapid cardiac pacing. After the 
cessation of rapid pacing, wall motion in the area perfused 
by the diseased coronary artery deteriorated significantly, 
whereas nonischemic zone shortening increased. Because 
the onset of contraction of the nonischemic segment oc-
curred earlier, its increased segment shortening was ex-
pended in stretching the ischemic myocardium during iso-
volumetric systole and no compensatory increase in 
ejection-phase shortening occurred. Therefore, two separate 
investigations (40,41) provided evidence to support the con-
cept that hyperkinesia of the nonischemic zone may contrib-
ute to dyssynergy of the ischemic zone. 
Clinical studies utilizing serial left ventriculography in 
patients with acute myocardial infarction have demon-
strated that regression of hyperkinesia of the noninfarct 
zone, as well as improvement in infarct area function, occurs 
over time. Because hyperkinesia may be due in part to 
increased adrenergic tone (37,45), a decrease in endogenous 
sympathetic stimulation or administration of a beta-blocking 
agent may contribute to resolution of hyperkinesia (46). Our 
observation that beta-blockade immediately reduced hyper-
contractility of noninfarcted tissue and lessened dyskinesia 
of the infarct zone supports the hypothesis that severely 
stunned myocardium may be flaccid and that its motion may 
be affected by contractile forces of the opposing wall. 
Because regional myocardial wall stress is related to systolic 
thinning and the radius of curvature of the dyskinetic seg-
ment (47), the ability of beta-blockers to immediately reduce 
dyskinesia may in part account for their ability to reduce 
cardiac rupture. In addition, because thrombolytic therapy 
has been associated with an early increase in mortality, 
potentially due to reperfusion injury and myocardial rupture 
(2), early beta-blockade may be of particular importance in 
these patients. 
Limitations. The changes observed in the infarct zone 
were very small. The main changes caused by metoprolol 
were a decrease in heart rate and an increase in left ventric-
ular volume, which made interpretation of wall motion 
changes difficult. Although analysis of regional wall motion 
from left ventriculograms is the standard clinical tool used to 
assess ventricular function after myocardial infarction, it has 
significant limitations. Acute changes in regional wall motion 
may be affected by preload, afterload, the motion of the 
entire heart and tethering of infarcted myocardium to the 
adjacent normal myocardium. Regional wall motion analysis 
does not allow determination of whether the improvement in 
wall motion is due to improved function or less paradoxic 
passive lengthening of the infarct zone. Measurement of 
regional wall stress and thickening would provide useful 
additional information. 
Conclusions. Our data demonstrate that intravenous 
beta-adrenergic blockade immediately reduced hyperkinesia 
of the noninfarct zone and enhanced infarct zone wall 
motion after reperfusion therapy. These data suggest that the 
primary action of beta-adrenergic blockade may be on 
noninfarcted myocardium, with a secondary reduction of 
infarct area dyssynergy achieved by decreasing hyperkine-
sia. Although the results of this study lend additional support 
for the role of early intravenous beta-blockade for patients 
with acute myocardial infarction, the changes observed in 
the infarct zone were small and their clinical relevance 
remains uncertain. 
We express appreciation to Florence Sheehan, MD for assistance in data 
analysis, Cheryl Diaz, BS for technical assistance and Phyllis McKinney for 
manuscript preparation. 
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